Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
HOLXMARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference
HOLX(NASDAQ:HOLX) MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference
Forecasting The Future: 6 Analyst Projections For Hologic
HOLXNeedham Reiterates Hold on Hologicto Hold
HOLXHologic Shares Resume Trade
HOLXHologic Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.24%
HOLXHologic And Biotheranostics To Present New Data At ASCO 2025 Highlighting Breast Cancer Index Test's Impact In Guiding Extended Endocrine Therapy Decisions For Over 2,800 HR+ Breast Cancer Patients
HOLXIs the Market Bullish or Bearish on Hologic?
HOLXStephens & Co. Maintains Overweight on Hologic, Lowers Price Target to $70
HOLXPrice Over Earnings Overview: Hologic
HOLXMorgan Stanley Maintains Equal-Weight on Hologic, Lowers Price Target to $65
HOLXBreaking Down Hologic: 10 Analysts Share Their Views
HOLXRBC Capital Maintains Sector Perform on Hologic, Lowers Price Target to $70
HOLXRaymond James Reiterates Outperform on Hologic, Lowers Price Target to $71
HOLXEvercore ISI Group Maintains In-Line on Hologic, Lowers Price Target to $62
HOLXNeedham Reiterates Hold on Hologicto Hold
HOLXHologic Sees Q3 Adj EPS $1.04-1.07 vs $1.10 Est; Sees Sales $1.000B-1.010B vs $1.03B Est
HOLXHologic Lowers FY2025 Adj EPS Guidance from $4.25-4.35 to $4.15-4.25 vs $4.26 Est; Affirms FY2025 Sales Guidance from $4.05B-4.10B to $4.05B-4.10B vs $4.08B Est
HOLXHologic Q2 Adj. EPS $1.03 Beats $1.02 Estimate, Sales $1.05B Beat $1.00B Estimate
HOLXHologic Announces It Will Present New New Data On Its AI-Powered Mammography Technology At Society Of Breast Imaging Annual Symposium In Colorado Springs April 24-25, 2025
HOLXHow Is The Market Feeling About Hologic?
HOLXHow Do Investors Really Feel About Hologic?
HOLX11 Analysts Have This To Say About Hologic
HOLXCitigroup Maintains Neutral on Hologic, Lowers Price Target to $70
HOLXHologic Granted FDA Clearance For Aptima SARS-CoV-2 Assay
HOLXMorgan Stanley Maintains Equal-Weight on Hologic, Lowers Price Target to $82
HOLXNeedham Reiterates Buy on Hologic, Maintains $90 Price Target
HOLXReported Earlies, Hologic Reports Preliminary Q1 FY25 Revenue Of $1.02B (+0.9% YoY), EPS Expected Near High-End Of Guidance
HOLXNeedham Reiterates Buy on Hologic, Maintains $90 Price Target
HOLXLooking Into Hologic's Recent Short Interest
HOLXRaymond James Maintains Outperform on Hologic, Raises Price Target to $95
HOLXMizuho Maintains Outperform on Hologic, Lowers Price Target to $87
HOLXUBS Maintains Neutral on Hologic, Raises Price Target to $90
HOLXRBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89
HOLXJP Morgan Maintains Overweight on Hologic, Raises Price Target to $94
HOLXHologic Intends To Enter Into An Accelerated Share Repurchase Agreement For $250M Of The Company's Common Stock.
HOLXHologic Sees FY25 Adj. EPS $4.25-$4.35, Revenue $4.15B-$4.20B; Sees Q1 Adj. EPS $1.00-$1.03, Revenue $1.025B-$1.035B
HOLXHologic Q4 2024 Adj. EPS $1.01, Inline, Sales $987.900M Beat $976.688M Estimate
HOLXHologic Recalls BioZorb Marker Due To Complications With Implanted Devices
HOLXHologic, Inc. Recalls Biozorb Marker Due To Reported Complications And Adverse Events With Implanted Devices - FDA
HOLXHologic's Return On Capital Employed Overview
HOLXPulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters.
Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue
HOLXRaymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know
HOLXRaymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00.
Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share.
A move to $83.00 would account for a 19.65% increase from the current share price.
Citigroup Maintains Neutral on Hologic, Lowers Price Target to $75
HOLXRaymond James Maintains Outperform on Hologic, Lowers Price Target to $83
HOLXSVB Leerink Maintains Outperform on Hologic, Lowers Price Target to $82
HOLX